Helsinn has a long-term commitment to bring its core values of quality, integrity and respect to China, offering innovative and high-quality products and improving the lives of Chinese cancer patients.
Helsinn has been present in China with a Representative Office since 2012 to coordinate clinical and regulatory activities. Currently, several of our cancer supportive care products are under registration with The China Food and Drug Administration (CFDA). In 2017 Helsinn Pharmaceuticals (Beijing) Co. Ltd., was established and the Shanghai branch was approved providing Helsinn with the platform to pursue Shanghai based commercial activities.
With the first products expected to be approved in 2018, Helsinn will expand its presence in China, with a Helsinn commercial organization focused on Shanghai and the pan-China collaboration with its partners, to prepare for the launch of future products and steadily grow to become a leading player in cancer care in China.